Safe Harbor Statement
Certain statements contained in this document are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Such statements include, but are not limited to, statements relating to 1) the creation and implementation of our strategic vision; 2) strengthening our position as a global leader in the life science market; 3) differentiating Invitrogen as the preferred supplier to our customers; 4) the development of new products; 5) the potential success of our acquisition strategy; 6) increasing our leadership in innovation, quality and customer service, acquisitions; and financial performance; 7) improving our gross margins and earnings per share; 8) increasing the speed and efficiency of new product development; 9) the development of key platform technologies; 10) extending our product line; 11) creating competitive advantages; 12) increasing spending on Research & Development; 13) our goal of becoming a leader in RNAi; 14) our belief that ZOOM Benchtop will be a true change agent in the field of proteomics; 15) the technology that we acquired from Genicon holding many possibilities across drug discovery, development and production; 16) improving our stock price; 17) our ability to operate more efficiently; 18) the acquisition and integration of BioReliance and Molecular Probes; 19) our entry into new markets; 20) our technology enabling research results and making the difficult possible; and 21) our goal to be a trusted and essential partner in all of the scientific endeavors of our customers. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from projected future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to: a) the growth rates for markets in which Invitrogen operates; b) whether Invitrogen can continue to launch successful new products and successfully integrate acquisitions into its operations; c) whether Invitrogen can successfully implement its core business strategy and manage growth; d) Invitrogen’s ability to strengthen its performance in quality and customer service, innovation, acquisitions, and financial performance; e) customer reaction to Invitrogen’s products and the valuation the public markets place on Invitrogen’s stock; f) whether Invitrogen’s efforts to drive out inefficiencies and other strategies can continue to improve our financial results; and other factors beyond Invitrogen’s direct control, in addition to competition and other risks and uncertainties detailed from time to time in the Company’s Securities and Exchange Commission filings.